Adolore Biotherapeutics, Inc. | WebDisclosure

Basculer en Français

10371	Companies
216166	Keywords
145880	Articles
114460	Press releases

Headlines Articles Press releases Adolore Biotherapeutics, Inc.

Home
Companies
Adolore Biotherapeutics, Inc.

PRESS RELEASE

published on 05/16/2024 at 16:00, 1 year 11 months ago

Adolore BioTherapeutics Announces Publication Demonstrating Carbonic Anhydrase-8 Gene Therapy (rdHSV-CA8) Decreased Pain-Sensing Neuronal Excitability by Activating Kv7 Voltage-Gated Potassium Channels
Adolore BioTherapeutics announces groundbreaking findings in gene therapy for chronic pain treatment, highlighting the value of non-opioid analgesics and progress with IND-enabling studies

Adolore BioTherapeutics Chronic Pain Gene Therapy Non-opioid Analgesics IND-enabling Studies
BRIEF

published on 03/04/2024 at 16:05, 2 years 2 months ago

Adolore BioTherapeutics obtient un brevet américain pour la thérapie génique CA8* dans le traitement de la douleur chronique

Adolore BioTherapeutics Thérapie Génique Traitement De La Douleur Chronique Solutions Sans Opioïdes Délivrance De Brevet
BRIEF

published on 03/04/2024 at 16:05, 2 years 2 months ago

Adolore BioTherapeutics Secures U.S. Patent for CA8* Gene Therapy in Chronic Pain Treatment

Adolore BioTherapeutics Gene Therapy Chronic Pain Treatment Opioid-Free Solutions Patent Issuance
PRESS RELEASE

published on 03/04/2024 at 16:00, 2 years 2 months ago

Adolore BioTherapeutics Announces Issuance of First U.S. Patent Covering CA8* Gene Therapies to Treat Chronic Pain
Adolore BioTherapeutics licenses patent and CA8* gene therapy technology from the University of Miami for opioid-free chronic pain treatment. Company progresses toward clinical testing and commercialization

University Of Miami Adolore BioTherapeutics Chronic Pain Opioid-free Gene Therapy
PRESS RELEASE

published on 01/30/2024 at 16:00, 2 years 3 months ago

Adolore BioTherapeutics to Present at the 5th Annual National Institutes of Health (NIH) HEAL Initiative Scientific Meeting
Adolore BioTherapeutics will present at the 5th Annual NIH HEAL Initiative Scientific Meeting regarding the gene therapy program for chronic pain associated with knee osteoarthritis. The program is supported by NIH/NINDS HEAL UH3 Award

Adolore BioTherapeutics Chronic Pain NIH HEAL Initiative Gene Therapy Osteoarthritis
PRESS RELEASE

published on 12/05/2023 at 16:30, 2 years 5 months ago

Adolore BioTherapeutics Presents Promising Preclinical Data Supporting Its Innovative Gene Therapy to Treat Chronic Pain
Adolore BioTherapeutics presented preclinical data supporting its innovative CA8* gene therapy as a long-acting local analgesic for chronic osteoarthritis knee pain management, aiming to replace opioids

Adolore BioTherapeutics CA8* Gene Therapy Chronic Pain Opioid-free Preclinical Data
PRESS RELEASE

published on 10/11/2023 at 16:00, 2 years 6 months ago

Adolore BioTherapeutics to Participate at the Virtual Investor Ask the CEO Conference
PRESS RELEASE

published on 10/03/2023 at 15:15, 2 years 7 months ago

NIN/NINDS HEAL Program Grants Prestigious UH3 Award to the University of Miami, Principal Investigator Roy C. Levitt M.D, to Fund Clinical Development of Adolore BioTherapeutics’ Gene Therapy Program for the Treatment of Chronic Osteoarthritis Knee Pain

Accesswire

Published on 05/09/2026 at 01:55, 15 hours 35 minutes ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 15 hours 50 minutes ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 16 hours ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 17 hours 30 minutes ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 18 hours 29 minutes ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 05/08/2026 at 20:38, 20 hours 51 minutes ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 22 hours 17 minutes ago

EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 22 hours 27 minutes ago

Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/08/2026 at 18:29, 23 hours 1 minute ago

Designated Person Notification
Published on 05/08/2026 at 18:29, 23 hours 1 minute ago

Designated Person Notification

Les Echos

Published on 05/07/2026 at 19:15, 1 day 22 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 1 day 22 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 1 day 22 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 1 day 22 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 1 day 22 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE